Prospective collection of data and biomaterial of COVID-19 at the location Würzburg

Prospective collection of data and biomaterial of COVID-19 at the location Würzburg - COVID-19 cohort Würzburg

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022402

Enrollment

400

Registered

2020-07-09

Start date

2020-05-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: All patients fulfilling the inclusion criteria undergo the following investigations: • Routine examination during hospital stay • Interview on symptoms, demographic information and pre-existi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Symptomatic COVID-19 infection, Hospital admission

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Mortality: Registration via clinical information system or (when consent has been given) by information of relatives or family doctor. Data is collected at baseline (during hospital stay), 3, 12 and 24 months after admission. Non-fatal complication: pulmonary co-infection, bloodstream infection, thromboembolic event. Data is collected at baseline (during hospital stay) via clinical information system. Quality of life: Registration via structured interview and standardized questionnaire (EQ-5D). Data is collected at 3, 12 and 24 months after admission.	—

Measure

Time frame

Mortality: Registration via clinical information system or (when consent has been given) by information of relatives or family doctor. Data is collected at baseline (during hospital stay), 3, 12 and 24 months after admission. Non-fatal complication: pulmonary co-infection, bloodstream infection, thromboembolic event. Data is collected at baseline (during hospital stay) via clinical information system. Quality of life: Registration via structured interview and standardized questionnaire (EQ-5D). Data is collected at 3, 12 and 24 months after admission.

—

Secondary

Measure	Time frame
identification of immune response or comorbidities due to COVID-19 infection	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026